• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺功能下降的分子决定因素:基因表达的多层次分析

Molecular Determinants of Lung Function Decline: A Multi- Level Analysis of Gene Expression.

作者信息

Elhusseini Zaid W, Rafique Omar, Ryu Min Hyung, Castaldi Peter, Sin Don D, Ruczinski Ingo, Hersh Craig P

机构信息

Harvard Medical School.

St. Paul's Hospital, University of British Columbia.

出版信息

Res Sq. 2025 Aug 19:rs.3.rs-7292685. doi: 10.21203/rs.3.rs-7292685/v1.

DOI:10.21203/rs.3.rs-7292685/v1
PMID:40894069
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12393492/
Abstract

BACKGROUND

Chronic obstructive pulmonary disease (COPD) is characterized by progressive lung function decline, commonly measured by forced expiratory volume in one second (FEV). Uncovering the genetic basis of FEV decline is essential for understanding COPD pathophysiology and for developing therapies. We hypothesized that gene expression patterns in inflammatory pathways are associated with FEV decline.

METHODS

We analyzed whole blood RNA-sequencing data from the 5 (n = 4,147) and 10 year visits (n = 435) in the COPDGene Study. Gene expression was assessed in three analyses: cross-sectional associations with FEV at two separate time points, association between year 5 gene expression and FEV changes from year 5-10, and longitudinal changes in both gene expression and FEV. A gene signature derived from the 5-year visit was linked to FEV decline across three intervals (baseline to 5 years, 5 to 10 years, and baseline to 10 years) and tested for validation in the ECLIPSE study.

RESULTS

Distinct gene sets emerged in the three analyses (Cross-sectional: 961 genes; FEV Change: 179; Longitudinal: 532). Only two genes ( and ) overlapped across all analyses, while unique genes (e.g., , and ) were context-specific. Pathway analysis of genes from the longitudinal analysis highlighted oxidative stress and immune processes. A 20-gene signature was derived, including 17 genes positively and three negatively associated with FEV. These signatures were significantly associated with FEV-related traits in COPDGene and ECLIPSE.

CONCLUSIONS

These findings reveal molecular markers of FEV decline, offering insights into COPD pathophysiology and potential therapeutic targets.

摘要

背景

慢性阻塞性肺疾病(COPD)的特征是肺功能进行性下降,通常用一秒用力呼气容积(FEV)来衡量。揭示FEV下降的遗传基础对于理解COPD的病理生理学和开发治疗方法至关重要。我们假设炎症途径中的基因表达模式与FEV下降有关。

方法

我们分析了COPDGene研究中5年(n = 4,147)和10年随访(n = 435)时的全血RNA测序数据。在三项分析中评估基因表达:在两个不同时间点与FEV的横断面关联、5年时的基因表达与5至10年FEV变化之间的关联,以及基因表达和FEV的纵向变化。从5年随访中得出的基因特征与三个时间段(基线至5年、5至十年以及基线至10年)的FEV下降相关,并在ECLIPSE研究中进行了验证测试。

结果

在三项分析中出现了不同的基因集(横断面:961个基因;FEV变化:179个;纵向:532个)。在所有分析中只有两个基因(和)重叠,而独特的基因(例如,和)是特定于上下文的。纵向分析中基因的通路分析突出了氧化应激和免疫过程。得出了一个由20个基因组成的特征,其中17个基因与FEV呈正相关,三个基因与FEV呈负相关。这些特征与COPDGene和ECLIPSE中与FEV相关的特征显著相关。

结论

这些发现揭示了FEV下降的分子标志物,为COPD的病理生理学和潜在治疗靶点提供了见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a00/12393492/972036a18271/nihpp-rs7292685v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a00/12393492/593ea9f4c5a4/nihpp-rs7292685v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a00/12393492/528909b04a8b/nihpp-rs7292685v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a00/12393492/972036a18271/nihpp-rs7292685v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a00/12393492/593ea9f4c5a4/nihpp-rs7292685v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a00/12393492/528909b04a8b/nihpp-rs7292685v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a00/12393492/972036a18271/nihpp-rs7292685v1-f0003.jpg

相似文献

1
Molecular Determinants of Lung Function Decline: A Multi- Level Analysis of Gene Expression.肺功能下降的分子决定因素:基因表达的多层次分析
Res Sq. 2025 Aug 19:rs.3.rs-7292685. doi: 10.21203/rs.3.rs-7292685/v1.
2
Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.慢性阻塞性肺疾病的长效吸入疗法(β受体激动剂、抗胆碱能药物和类固醇):一项网状荟萃分析。
Cochrane Database Syst Rev. 2014 Mar 26;2014(3):CD010844. doi: 10.1002/14651858.CD010844.pub2.
3
Self-management interventions for people with chronic obstructive pulmonary disease.针对慢性阻塞性肺疾病患者的自我管理干预措施。
Cochrane Database Syst Rev. 2022 Jan 10;1(1):CD002990. doi: 10.1002/14651858.CD002990.pub4.
4
Indacaterol, a once-daily beta2-agonist, versus twice-daily beta₂-agonists or placebo for chronic obstructive pulmonary disease.茚达特罗,一种每日一次的β2受体激动剂,与每日两次的β2受体激动剂或安慰剂治疗慢性阻塞性肺疾病的比较
Cochrane Database Syst Rev. 2015 Jan 10;1(1):CD010139. doi: 10.1002/14651858.CD010139.pub2.
5
Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).溴化乌美溴铵对比安慰剂用于慢性阻塞性肺疾病(COPD)患者。
Cochrane Database Syst Rev. 2017 Jun 20;6(6):CD011897. doi: 10.1002/14651858.CD011897.pub2.
6
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.吸入性糖皮质激素与慢性阻塞性肺疾病患者的肺炎风险
Cochrane Database Syst Rev. 2014 Mar 10;2014(3):CD010115. doi: 10.1002/14651858.CD010115.pub2.
7
Long-acting beta2-agonists for chronic obstructive pulmonary disease.用于慢性阻塞性肺疾病的长效β2受体激动剂。
Cochrane Database Syst Rev. 2013 Oct 15;2013(10):CD010177. doi: 10.1002/14651858.CD010177.pub2.
8
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).针对携带 II 类 CFTR 基因突变(最常见的是 F508del)的囊性纤维化患者的校正治疗(有或没有增效剂)。
Cochrane Database Syst Rev. 2023 Nov 20;11(11):CD010966. doi: 10.1002/14651858.CD010966.pub4.
9
Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis.常规胸部物理治疗与其他气道清除技术在囊性纤维化中的比较。
Cochrane Database Syst Rev. 2023 May 5;5(5):CD002011. doi: 10.1002/14651858.CD002011.pub3.
10
Pulmonary rehabilitation for chronic obstructive pulmonary disease.慢性阻塞性肺疾病的肺康复治疗
Cochrane Database Syst Rev. 2015 Feb 23;2015(2):CD003793. doi: 10.1002/14651858.CD003793.pub3.

本文引用的文献

1
Blood Gene Expression and Immune Cell Subtypes Associated with Chronic Obstructive Pulmonary Disease Exacerbations.与慢性阻塞性肺疾病加重相关的血液基因表达和免疫细胞亚型。
Am J Respir Crit Care Med. 2023 Aug 1;208(3):247-255. doi: 10.1164/rccm.202301-0085OC.
2
Identification of novel genetic variants, including PIM1 and LINC01491, with ICD-10 based diagnosis of pulmonary arterial hypertension in the UK Biobank cohort.在英国生物银行队列中,基于国际疾病分类第10版(ICD-10)诊断肺动脉高压,鉴定包括PIM1和LINC01491在内的新型基因变异。
Front Drug Discov (Lausanne). 2023;3. doi: 10.3389/fddsv.2023.1127736. Epub 2023 Feb 8.
3
Inference of chronic obstructive pulmonary disease with deep learning on raw spirograms identifies new genetic loci and improves risk models.
利用深度学习对原始肺量计图进行慢性阻塞性肺疾病推断可识别新的基因位点并改进风险模型。
Nat Genet. 2023 May;55(5):787-795. doi: 10.1038/s41588-023-01372-4. Epub 2023 Apr 17.
4
Genetic diversity fuels gene discovery for tobacco and alcohol use.遗传多样性为烟草和酒精使用的基因发现提供了动力。
Nature. 2022 Dec;612(7941):720-724. doi: 10.1038/s41586-022-05477-4. Epub 2022 Dec 7.
5
Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial.抗ST2药物阿斯特戈利单抗治疗慢性阻塞性肺疾病(COPD-ST2OP):一项2a期安慰剂对照试验
Lancet Respir Med. 2022 May;10(5):469-477. doi: 10.1016/S2213-2600(21)00556-7. Epub 2022 Mar 24.
6
Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial.特泊替尼治疗中重度 COPD 患者的安全性和有效性:一项遗传关联研究和随机、双盲、2a 期临床试验。
Lancet Respir Med. 2021 Nov;9(11):1288-1298. doi: 10.1016/S2213-2600(21)00167-3. Epub 2021 Jul 21.
7
Blood RNA sequencing shows overlapping gene expression across COPD phenotype domains.血液 RNA 测序显示 COPD 表型领域存在重叠的基因表达。
Thorax. 2022 Feb;77(2):115-122. doi: 10.1136/thoraxjnl-2020-216401. Epub 2021 Jun 24.
8
Inflammatory biomarker relationships with helper T cell GPR15 expression and cannabis and tobacco smoking.炎症生物标志物与辅助性 T 细胞 GPR15 表达以及大麻和烟草吸烟的关系。
J Psychosom Res. 2021 Feb;141:110326. doi: 10.1016/j.jpsychores.2020.110326. Epub 2020 Dec 6.
9
: batch effect adjustment for RNA-seq count data.RNA测序计数数据的批次效应调整
NAR Genom Bioinform. 2020 Sep;2(3):lqaa078. doi: 10.1093/nargab/lqaa078. Epub 2020 Sep 21.
10
Regulatory mechanism of NOV/CCN3 in the inflammation and apoptosis of lung epithelial alveolar cells upon lipopolysaccharide stimulation.NOV/CCN3 在脂多糖刺激肺上皮肺泡细胞炎症和凋亡中的调控机制。
Mol Med Rep. 2020 Apr;21(4):1872-1880. doi: 10.3892/mmr.2019.10655. Epub 2019 Sep 9.